Entera Bio Ltd. (ENTX)

NASDAQ: ENTX · IEX Real-Time Price · USD
2.36
0.21 (9.77%)
At close: May 16, 2022 4:00 PM
2.40
0.04 (1.69%)
After-hours:May 16, 2022 4:03 PM EDT
Market Cap67.98M
Revenue (ttm)482,000
Net Income (ttm)-6.48M
Shares Out28.80M
EPS (ttm)-0.47
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume43,779
Open2.11
Previous Close2.15
Day's Range1.95 - 2.36
52-Week Range1.72 - 8.68
Beta1.65
AnalystsBuy
Price Target6.89 (+191.9%)
Earnings DateMay 12, 2022

About ENTX

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreeme...

IndustryBiotechnology
IPO DateJun 28, 2018
CEOAdam Gridley
Employees18
Stock ExchangeNASDAQ
Ticker SymbolENTX
Full Company Profile

Financial Performance

In 2021, Entera Bio's revenue was $571,000, an increase of 56.44% compared to the previous year's $365,000. Losses were -$12.19 million, 8.66% more than in 2020.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for ENTX stock is "Buy." The 12-month stock price forecast is 6.89, which is an increase of 191.95% from the latest price.

Price Target
$6.89
(191.95% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Entera Bio Reports First Quarter 2022 Financial Results and Business Highlights

BOSTON and JERUSALEM, May 12, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced its financial and oper...

4 days ago - GlobeNewsWire

Follow the Insiders and Buy the Dip in These 3 Stocks

These three biotech companies have all had insiders buying shares recently. That's a good sign for the future of their treatments.

Other symbols:LGVNTCON
1 week ago - InvestorPlace

Recession Fears are Creating a Golden Opportunity for Biotech Stocks

Biotech stocks are hard for novice investors to successfully profit from, but it's worth your time to learn the techniques now. The post Recession Fears are Creating a Golden Opportunity for Biotech Sto...

1 month ago - InvestorPlace

Entera Bio Reports Financial Results for the Year Ended December 31, 2021

— EB613 expected to commence pivotal Phase 3 Osteoporosis trial in 2022 — — New EB612 formulation for Hypoparathyroidism trial planned in 2022 — — Oral delivery technology platform advances with more in...

2 months ago - GlobeNewsWire

Entera Bio to Report Business and Financial Results for the Year Ended December 31, 2021 on March 8, 2022

BOSTON and JERUSALEM, March 03, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today it will report busin...

2 months ago - GlobeNewsWire

Entera Bio to Present at Aegis Virtual Conference on February 23rd

BOSTON and JERUSALEM, Israel, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced that the Comp...

2 months ago - GlobeNewsWire

Entera Bio Announces Successful EB613 End-of-Phase 2 Meeting with FDA: FDA Agrees to Phase 3 Twelve Month Study with ...

‒ Company plans to initiate multi-national Phase 3 Trial in 2022 ‒ ‒ Company plans to initiate multi-national Phase 3 Trial in 2022 ‒

4 months ago - GlobeNewsWire

Entera Bio Reports Third Quarter 2021 Financial Results

‒ Two Presentations at ASB M R , including Late Breaker, on Phase 2 EB613 Clinical Trial Results in Osteoporosis ‒

6 months ago - GlobeNewsWire

Entera Bio Publishes Key Study Describing its Oral Delivery Technology Platform for Biologic Drugs

‒Study describes a dual mechanism of action approach to oral drug delivery of large molecules, the “Holy Grail” of drug development.

6 months ago - GlobeNewsWire

7 Biotech Penny Stocks With Huge Catalysts Coming in 2022

With a new year fast approaching, these biotech penny stocks may benefit from the shifting winds in the broader healthcare market. The post 7 Biotech Penny Stocks With Huge Catalysts Coming in 2022 appe...

Other symbols:ATRXBLUCYDYDFFN
7 months ago - InvestorPlace

Entera Bio's Formulated Human Parathyroid Hormone Shows Encouraging BMD Data

Entera Bio Ltd (NASDAQ: ENTX) has presented the 6-month bone mineral density (BMD) data from its Phase 2 trial of EB613, an oral formulation of human parathyroid hormone (PTH), for osteoporosis.  The Ph...

7 months ago - Benzinga

Entera Bio Presents Positive Phase 2 6-Month Bone Mineral Density Data for Oral PTH Formulation at Late Breaker ASBMR...

Increases in lumbar spine, femoral neck and total hip BMD demonstrated with EB613

7 months ago - GlobeNewsWire

Entera Bio Selected for Late Breaking Oral Presentation of Phase 2 6-Month Osteoporosis Data at ASBMR 2021 Annual Mee...

‒ Second of Two Presentations to be Delivered by Entera ‒

8 months ago - GlobeNewsWire

Entera Bio to Conduct Annual Shareholders Meeting on October 4, 2021

BOSTON and JERUSALEM, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced it will host its annu...

8 months ago - GlobeNewsWire

Entera Bio to Present at H.C. Wainwright 23rd Annual Global Investment Conference

BOSTON and JERUSALEM, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the Company's CEO Spi...

8 months ago - GlobeNewsWire

New Strong Sell Stocks for August 19th

ALIM, BEEM, CDR, ENTX, and IDEX have been added to the Zacks Rank #5 (Strong Sell) List on August 19, 2021.

Other symbols:ALIMBEEMCDRIDEX
8 months ago - Zacks Investment Research

Entera Bio Reports Second Quarter 2021 Financial Results and Provides Clinical Updates

‒ Phase 2 EB613 Clinical Trial in Osteoporosi s Achieves 6-month Bone Mineral Density Endpoint; Primary and Key Secondary Endpoints Met ‒

9 months ago - GlobeNewsWire

Entera Bio to Report Business and Financial Results for the Quarter ended June 30, 2021, on August 16, 2021

BOSTON and JERUSALEM, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report business and...

9 months ago - GlobeNewsWire

Entera Bio to Present Phase 2 EB613 Oral PTH Osteoporosis Treatment 3-Month Findings at the American Society for Bone...

‒ The Study's Primary Endpoint was Met; P1NP, a Biochemical Marker of Bone Formation, was Significantly Increased at Month 3 in EB613 2.5 mg Treatment Group Versus Placebo ‒

9 months ago - GlobeNewsWire

Entera Bio to Conduct Conference Call on June 30 to Discuss Phase 2 Results for EB613 Positioned to be the First Oral...

BOSTON and JERUSALEM, June 28, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced it will conduct a con...

10 months ago - GlobeNewsWire

Entera (ENTX) Up on Positive Results From Osteoporosis Drug

Entera (ENTX) gains on positive results from a mid-stage study on its osteoporosis candidate at six months.

10 months ago - Zacks Investment Research

Where Might Entera Bio Stock End Up After Rallying Wednesday

Entera Bio Ltd (NASDAQ: ENTX) shares rallied higher Wednesday after the company announced it saw positive results from its final six-month bone mineral density results from the completed Phase 2 clinica...

10 months ago - Benzinga

ENTX Stock: The Huge FDA News Sending Entera Bio Soaring

Today, investors in ENTX stock are seeing gains of approximately 40% as the company announced results from one of its clinical trials. The post ENTX Stock: The Huge FDA News Sending Entera Bio Soaring a...

10 months ago - InvestorPlace

Why Entera Bio, Orphazyme, Bellerophon Are Moving Today

Entera Bio Ltd. (NASDAQ: ENTX), Orphazyme A/S (NASDAQ: ORPH) and Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) are among the biggest biopharma movers Wednesday.

Other symbols:BLPH
10 months ago - Benzinga

Why Entera Bio Shares Are Skyrocketing Today

Entera Bio Ltd (NASDAQ: ENTX) shares are trading higher by 47.66% at $6.63 Wednesday after the company announced the topline Phase 2 clinical trial of EB613 met its primary and key secondary endpoints. ...

10 months ago - Benzinga